Regulation of Mesothelial Cell Fate during Development and Human Diseases
Abstract
:1. Introduction
2. MCs and Wt1 Gene
2.1. General Information on MCs
2.2. Wt1 in MC Differentiation
3. Differentiation of MCs into Fibroblasts
3.1. Differentiation of MCs into Fibroblasts Related to Peritoneal Dialysis (PD)
3.2. Differentiation of Wt1+ MCs into Fibroblasts
3.3. Differentiation of MCs into Myofibroblasts in Cancer
4. Contribution of MCs to Blood Vessels
4.1. Wt1+ MCs in Heart Development
4.2. Role of Wt1 in MC Differentiation Related to Tumor Angiogenesis
5. MCs and Adipocytes
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Van Baal, J.O.; Van de Vijver, K.K.; Nieuwland, R.; van Noorden, C.J.; van Driel, W.J.; Sturk, A.; Kenter, G.G.; Rikkert, L.G.; Lok, C.A. The histophysiology and pathophysiology of the peritoneum. Tissue Cell 2017, 49, 95–105. [Google Scholar] [CrossRef] [PubMed]
- Carmona, R.; Gonzalez-Iriarte, M.; Perez-Pomares, J.M.; Munoz-Chapuli, R. Localization of the Wilm’s tumour protein WT1 in avian embryos. Cell Tissue Res. 2001, 303, 173–186. [Google Scholar] [CrossRef] [PubMed]
- Affo, S.; Nair, A.; Brundu, F.; Ravichandra, A.; Bhattacharjee, S.; Matsuda, M.; Chin, L.; Filliol, A.; Wen, W.; Song, X.; et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 2021, 39, 866–882.e11. [Google Scholar] [CrossRef]
- Dominguez, C.X.; Muller, S.; Keerthivasan, S.; Koeppen, H.; Hung, J.; Gierke, S.; Breart, B.; Foreman, O.; Bainbridge, T.W.; Castiglioni, A.; et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov. 2020, 10, 232–253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Y.; Lua, I.; French, S.W.; Asahina, K. Role of TGF-beta signaling in differentiation of mesothelial cells to vitamin A-poor hepatic stellate cells in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2016, 310, G262–G272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lua, I.; Li, Y.; Zagory, J.A.; Wang, K.S.; French, S.W.; Sevigny, J.; Asahina, K. Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. J. Hepatol. 2016, 64, 1137–1146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kawanishi, K. Diverse properties of the mesothelial cells in health and disease. Pleura Peritoneum 2016, 1, 79–89. [Google Scholar] [CrossRef] [PubMed]
- Bodega, F.; Pecchiari, M.; Sironi, C.; Porta, C.; Arnaboldi, F.; Barajon, I.; Agostoni, E. Lubricating effect of sialomucin and hyaluronan on pleural mesothelium. Respir. Physiol. Neurobiol. 2012, 180, 34–39. [Google Scholar] [CrossRef] [PubMed]
- Pecchiari, M.; Sartori, P.; Conte, V.; D’Angelo, E.; Moscheni, C. Friction and morphology of pleural mesothelia. Respir. Physiol. Neurobiol. 2016, 220, 17–24. [Google Scholar] [CrossRef]
- Mutsaers, S.E. Mesothelial cells: Their structure, function and role in serosal repair. Respirology 2002, 7, 171–191. [Google Scholar] [CrossRef]
- Kothari, H.; Kaur, G.; Sahoo, S.; Idell, S.; Rao, L.V.; Pendurthi, U. Plasmin enhances cell surface tissue factor activity in mesothelial and endothelial cells. J. Thromb. Haemost. 2009, 7, 121–131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mutsaers, S.E.; Prele, C.M.; Pengelly, S.; Herrick, S.E. Mesothelial cells and peritoneal homeostasis. Fertil. Steril. 2016, 106, 1018–1024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ohtsuka, A.; Yamana, S.; Murakami, T. Localization of membrane-associated sialomucin on the free surface of mesothelial cells of the pleura, pericardium, and peritoneum. Histochem. Cell. Biol. 1997, 107, 441–447. [Google Scholar] [CrossRef] [PubMed]
- Soliman, F.; Ye, L.; Jiang, W.; Hargest, R. Targeting Hyaluronic Acid and Peritoneal Dissemination in Colorectal Cancer. Clin. Colorectal Cancer 2021, 21, e126–e134. [Google Scholar] [CrossRef] [PubMed]
- Itano, N.; Sawai, T.; Yoshida, M.; Lenas, P.; Yamada, Y.; Imagawa, M.; Shinomura, T.; Hamaguchi, M.; Yoshida, Y.; Ohnuki, Y.; et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 1999, 274, 25085–25092. [Google Scholar] [CrossRef] [Green Version]
- Camenisch, T.D.; Spicer, A.P.; Brehm-Gibson, T.; Biesterfeldt, J.; Augustine, M.L.; Calabro, A., Jr.; Kubalak, S.; Klewer, S.E.; McDonald, J.A. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 2000, 106, 349–360. [Google Scholar] [CrossRef] [Green Version]
- Yung, S.; Chan, T.M. Pathophysiology of the peritoneal membrane during peritoneal dialysis: The role of hyaluronan. J. Biomed. Biotechnol. 2011, 2011, 180594. [Google Scholar] [CrossRef] [Green Version]
- Yung, S.; Chan, T.M. Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: The role of mesothelial cells. Mediat. Inflamm. 2012, 2012, 484167. [Google Scholar] [CrossRef] [Green Version]
- Ivanov, S.; Gallerand, A.; Gros, M.; Stunault, M.I.; Merlin, J.; Vaillant, N.; Yvan-Charvet, L.; Guinamard, R.R. Mesothelial cell CSF1 sustains peritoneal macrophage proliferation. Eur. J. Immunol. 2019, 49, 2012–2018. [Google Scholar] [CrossRef]
- Hausmann, M.J.; Rogachev, B.; Weiler, M.; Chaimovitz, C.; Douvdevani, A. Accessory role of human peritoneal mesothelial cells in antigen presentation and T-cell growth. Kidney Int. 2000, 57, 476–486. [Google Scholar] [CrossRef]
- Batra, H.; Antony, V.B. The pleural mesothelium in development and disease. Front. Physiol. 2014, 5, 284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zsiros, V.; Kiss, A.L. Cellular and molecular events of inflammation induced transdifferentiation (EMT) and regeneration (MET) in mesenteric mesothelial cells. Inflamm. Res. 2020, 69, 1173–1179. [Google Scholar] [CrossRef] [PubMed]
- Chau, Y.Y.; Hastie, N.D. The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet. 2012, 28, 515–524. [Google Scholar] [CrossRef]
- Gessler, M.; Poustka, A.; Cavenee, W.; Neve, R.L.; Orkin, S.H.; Bruns, G.A. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990, 343, 774–778. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kreidberg, J.A.; Sariola, H.; Loring, J.M.; Maeda, M.; Pelletier, J.; Housman, D.; Jaenisch, R. WT-1 Is Required for Early Kidney Development. Cell 1993, 74, 679–691. [Google Scholar] [CrossRef]
- Herzer, U. The Wilms tumor suppressor gene Wt1 is required for development of the spleen. Curr. Biol. 1999, 9, 837–840. [Google Scholar] [CrossRef] [Green Version]
- Moore, A.W.; McInnes, L.; Kreidberg, J.; Hastie, N.D.; Schedl, A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development 1999, 126, 1845–1857. [Google Scholar] [CrossRef] [PubMed]
- Akpa, M.M.; Iglesias, D.M.; Chu, L.L.; Cybulsky, M.; Bravi, C.; Goodyer, P.R. Wilms tumor suppressor, WT1, suppresses epigenetic silencing of the beta-catenin gene. J. Biol. Chem. 2015, 290, 2279–2288. [Google Scholar] [CrossRef] [Green Version]
- Essafi, A.; Webb, A.; Berry, R.L.; Slight, J.; Burn, S.F.; Spraggon, L.; Velecela, V.; Martinez-Estrada, O.M.; Wiltshire, J.H.; Roberts, S.G.; et al. A Wt1-controlled chromatin switching mechanism underpins tissue-specific wnt4 activation and repression. Dev. Cell. 2011, 21, 559–574. [Google Scholar] [CrossRef] [Green Version]
- Martinez-Estrada, O.M.; Lettice, L.A.; Essafi, A.; Guadix, J.A.; Slight, J.; Velecela, V.; Hall, E.; Reichmann, J.; Devenney, P.S.; Hohenstein, P.; et al. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat. Genet. 2010, 42, 89–93. [Google Scholar] [CrossRef]
- Wu, M.; Smith, C.L.; Hall, J.A.; Lee, I.; Luby-Phelps, K.; Tallquist, M.D. Epicardial spindle orientation controls cell entry into the myocardium. Dev. Cell. 2010, 19, 114–125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, B.; Ma, Q.; Rajagopal, S.; Wu, S.M.; Domian, I.; Rivera-Feliciano, J.; Jiang, D.; von Gise, A.; Ikeda, S.; Chien, K.R.; et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 2008, 454, 109–113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hastie, N.D. Wilms’ tumour 1 (WT1) in development, homeostasis and disease. Development 2017, 144, 2862–2872. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chau, Y.Y.; Brownstein, D.; Mjoseng, H.; Lee, W.C.; Buza-Vidas, N.; Nerlov, C.; Jacobsen, S.E.; Perry, P.; Berry, R.; Thornburn, A.; et al. Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1. PLoS Genet. 2011, 7, e1002404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grassmann, A.; Gioberge, S.; Moeller, S.; Brown, G. ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol. Dial. Transplant. 2005, 20, 2587–2593. [Google Scholar] [CrossRef]
- Morgan, L.W.; Wieslander, A.; Davies, M.; Horiuchi, T.; Ohta, Y.; Beavis, M.J.; Craig, K.J.; Williams, J.D.; Topley, N. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int. 2003, 64, 1854–1866. [Google Scholar] [CrossRef] [Green Version]
- Witowski, J.; Wisniewska, J.; Korybalska, K.; Bender, T.O.; Breborowicz, A.; Gahl, G.M.; Frei, U.; Passlick-Deetjen, J.; Jorres, A. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J. Am. Soc. Nephrol. 2001, 12, 2434–2441. [Google Scholar] [CrossRef]
- Williams, J.D.; Craig, K.J.; Topley, N.; Von Ruhland, C.; Fallon, M.; Newman, G.R.; Mackenzie, R.K.; Williams, G.T. Morphologic changes in the peritoneal membrane of patients with renal disease. J. Am. Soc. Nephrol. 2002, 13, 470–479. [Google Scholar] [CrossRef]
- Jimenez-Heffernan, J.A.; Aguilera, A.; Aroeira, L.S.; Lara-Pezzi, E.; Bajo, M.A.; del Peso, G.; Ramirez, M.; Gamallo, C.; Sanchez-Tomero, J.A.; Alvarez, V.; et al. Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch. 2004, 444, 247–256. [Google Scholar] [CrossRef]
- Yáñez-Mó, M. Peritoneal Dialysis and Epithelial-to-Mesenchymal Transition of Mesothelial Cells. N. Engl. J. Med. 2003, 348, 403–413. [Google Scholar] [CrossRef]
- Nasreen, N.; Mohammed, K.A.; Mubarak, K.K.; Baz, M.A.; Akindipe, O.A.; Fernandez-Bussy, S.; Antony, V.B. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297, L115–L124. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, A.H.; Chen, J.Y.; Lin, J.K. Myofibroblastic conversion of mesothelial cells. Kidney Int. 2003, 63, 1530–1539. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, Q.; Yang, M.; Lan, H.; Yu, X. miR-30a negatively regulates TGF-beta1-induced epithelial-mesenchymal transition and peritoneal fibrosis by targeting Snai1. Am. J. Pathol. 2013, 183, 808–819. [Google Scholar] [CrossRef] [PubMed]
- Loureiro, J.; Schilte, M.; Aguilera, A.; Albar-Vizcaino, P.; Ramirez-Huesca, M.; Perez-Lozano, M.L.; Gonzalez-Mateo, G.; Aroeira, L.S.; Selgas, R.; Mendoza, L.; et al. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrol. Dial. Transplant. 2010, 25, 1098–1108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, M.A.; Shin, K.S.; Kim, J.H.; Kim, Y.I.; Chung, S.S.; Park, S.H.; Kim, Y.L.; Kang, D.H. HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J. Am. Soc. Nephrol. 2009, 20, 567–581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bajo, M.A.; Perez-Lozano, M.L.; Albar-Vizcaino, P.; del Peso, G.; Castro, M.J.; Gonzalez-Mateo, G.; Fernandez-Perpen, A.; Aguilera, A.; Sanchez-Villanueva, R.; Sanchez-Tomero, J.A.; et al. Low-GDP peritoneal dialysis fluid (‘balance’) has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid. Nephrol. Dial. Transplant. 2011, 26, 282–291. [Google Scholar] [CrossRef] [Green Version]
- Hirahara, I.; Ishibashi, Y.; Kaname, S.; Kusano, E.; Fujita, T. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol. Dial. Transplant. 2009, 24, 437–447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Strippoli, R.; Benedicto, I.; Foronda, M.; Perez-Lozano, M.L.; Sanchez-Perales, S.; Lopez-Cabrera, M.; Del Pozo, M.A. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition. J. Cell Sci. 2010, 123 Pt 24, 4321–4331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Strippoli, R.; Benedicto, I.; Perez Lozano, M.L.; Cerezo, A.; Lopez-Cabrera, M.; del Pozo, M.A. Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-kappaB/Snail1 pathway. Dis Models Mech 2008, 1, 264–274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Strippoli, R.; Benedicto, I.; Perez Lozano, M.L.; Pellinen, T.; Sandoval, P.; Lopez-Cabrera, M.; del Pozo, M.A. Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells. PLoS ONE 2012, 7, e31492. [Google Scholar] [CrossRef] [PubMed]
- Tan, X.; Li, Y.; Liu, Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 2006, 17, 3382–3393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, L.; Lei, W.; Wang, X.; Tang, Y.; Song, J. Glucocorticoid induces mesenchymal-to-epithelial transition and inhibits TGF-beta1-induced epithelial-to-mesenchymal transition and cell migration. FEBS Lett. 2010, 584, 4646–4654. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, Y.T.; Chang, Y.T.; Pan, S.Y.; Chou, Y.H.; Chang, F.C.; Yeh, P.Y.; Liu, Y.H.; Chiang, W.C.; Chen, Y.M.; Wu, K.D.; et al. Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury. J. Am. Soc. Nephrol. 2014, 25, 2847–2858. [Google Scholar] [CrossRef] [Green Version]
- Jaster, R. Molecular regulation of pancreatic stellate cell function. Mol. Cancer 2004, 3, 26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Riopel, M.M.; Li, J.; Liu, S.; Leask, A.; Wang, R. beta1 integrin-extracellular matrix interactions are essential for maintaining exocrine pancreas architecture and function. Lab. Invest. 2013, 93, 31–40. [Google Scholar] [CrossRef] [Green Version]
- Zimmermann, A.; Gloor, B.; Kappeler, A.; Uhl, W.; Friess, H.; Buchler, M.W. Pancreatic stellate cells contribute to regeneration early after acute necrotising pancreatitis in humans. Gut 2002, 51, 574–578. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ariza, L.; Canete, A.; Rojas, A.; Munoz-Chapuli, R.; Carmona, R. Role of the Wilms’ tumor suppressor gene Wt1 in pancreatic development. Dev. Dyn. 2018, 247, 924–933. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ariza, L.; Rojas, A.; Munoz-Chapuli, R.; Carmona, R. The Wilms’ tumor suppressor gene regulates pancreas homeostasis and repair. PLoS Genet. 2019, 15, e1007971. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Wang, J.; Asahina, K. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Proc. Natl. Acad. Sci. USA 2013, 110, 2324–2329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kisseleva, T.; Cong, M.; Paik, Y.; Scholten, D.; Jiang, C.; Benner, C.; Iwaisako, K.; Moore-Morris, T.; Scott, B.; Tsukamoto, H.; et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. USA 2012, 109, 9448–9453. [Google Scholar] [CrossRef]
- Mederacke, I.; Hsu, C.C.; Troeger, J.S.; Huebener, P.; Mu, X.; Dapito, D.H.; Pradere, J.P.; Schwabe, R.F. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 2013, 4, 2823. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kendall, T.J.; Duff, C.M.; Boulter, L.; Wilson, D.H.; Freyer, E.; Aitken, S.; Forbes, S.J.; Iredale, J.P.; Hastie, N.D. Embryonic mesothelial-derived hepatic lineage of quiescent and heterogenous scar-orchestrating cells defined but suppressed by WT1. Nat. Commun. 2019, 10, 4688. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kenny, H.A.; Dogan, S.; Zillhardt, M.; Mitra, A.; Yamada, S.D.; Krausz, T.; Lengyel, E. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat. Res. 2009, 149, 335–351. [Google Scholar] [PubMed] [Green Version]
- Kenny, H.A.; Krausz, T.; Yamada, S.D.; Lengyel, E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int. J. Cancer 2007, 121, 1463–1472. [Google Scholar] [CrossRef] [PubMed]
- Matte, I. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer 2014, 14, 288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matte, I.; Lane, D.; Laplante, C.; Rancourt, C.; Piche, A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am. J. Cancer Res. 2012, 2, 566–580. [Google Scholar] [PubMed]
- Rynne-Vidal, A.; Au-Yeung, C.L.; Jimenez-Heffernan, J.A.; Perez-Lozano, M.L.; Cremades-Jimeno, L.; Barcena, C.; Cristobal-Garcia, I.; Fernandez-Chacon, C.; Yeung, T.L.; Mok, S.C.; et al. Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. J. Pathol. 2017, 242, 140–151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tan, D.S.P.; Agarwal, R.; Kaye, S.B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006, 7, 925–934. [Google Scholar] [CrossRef]
- Casey, R.C.; Burleson, K.M.; Skubitz, K.M.; Pambuccian, S.E.; Oegema, T.R.; Ruff, L.E.; Skubitz, A.P.N. β1-Integrins Regulate the Formation and Adhesion of Ovarian Carcinoma Multicellular Spheroids. Am. J. Pathol. 2001, 159, 2071–2080. [Google Scholar] [CrossRef]
- Ohyagi-Hara, C.; Sawada, K.; Kamiura, S.; Tomita, Y.; Isobe, A.; Hashimoto, K.; Kinose, Y.; Mabuchi, S.; Hisamatsu, T.; Takahashi, T.; et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin alpha5 expression. Am. J. Pathol. 2013, 182, 1876–1889. [Google Scholar] [CrossRef] [PubMed]
- Gao, Q.; Yang, Z.; Xu, S.; Li, X.; Yang, X.; Jin, P.; Liu, Y.; Zhou, X.; Zhang, T.; Gong, C.; et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J. Exp. Med. 2019, 216, 688–703. [Google Scholar] [CrossRef] [Green Version]
- Murata, T.; Mizushima, H.; Chinen, I.; Moribe, H.; Yagi, S.; Hoffman, R.M.; Kimura, T.; Yoshino, K.; Ueda, Y.; Enomoto, T.; et al. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer Res. 2011, 71, 6633–6642. [Google Scholar] [CrossRef] [Green Version]
- Yoshihara, M.; Kajiyama, H.; Yokoi, A.; Sugiyama, M.; Koya, Y.; Yamakita, Y.; Liu, W.; Nakamura, K.; Moriyama, Y.; Yasui, H.; et al. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway. Int. J. Cancer 2020, 146, 2268–2280. [Google Scholar] [CrossRef] [Green Version]
- Fujikake, K.; Kajiyama, H.; Yoshihara, M.; Nishino, K.; Yoshikawa, N.; Utsumi, F.; Suzuki, S.; Niimi, K.; Sakata, J.; Mitsui, H.; et al. A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-beta derived from ovarian cancer. Oncol. Rep. 2018, 39, 193–200. [Google Scholar] [PubMed] [Green Version]
- Zebrowski, B.K.; Liu, W.; Ramirez, K.; Akagi, Y.; Mills, G.B.; Ellis, L.M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 1999, 6, 373–378. [Google Scholar] [CrossRef] [PubMed]
- Mandl-Weber, S.; Cohen, C.D.; Haslinger, B.; Kretzler, M.; Sitter, T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int. 2002, 61, 570–578. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liao, S.; Liu, J.; Lin, P.; Shi, T.; Jain, R.K.; Xu, L. TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin. Cancer Res. 2011, 17, 1415–1424. [Google Scholar] [CrossRef] [Green Version]
- Sako, A.; Kitayama, J.; Yamaguchi, H.; Kaisaki, S.; Suzuki, H.; Fukatsu, K.; Fujii, S.; Nagawa, H. Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cell on the development of peritoneal metastasis. J. Surg. Res. 2003, 115, 113–120. [Google Scholar] [CrossRef]
- Stadlmann, S.; Amberger, A.; Pollheimer, J.; Gastl, G.; Offner, F.A.; Margreiter, R.; Zeimet, A.G. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol. Oncol. 2005, 97, 784–789. [Google Scholar] [CrossRef]
- Davis, A.; Tinker, A.V.; Friedlander, M. “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol. Oncol. 2014, 133, 624–631. [Google Scholar] [CrossRef]
- Pujade-Lauraine, E.; Hilpert, F.; Weber, B.; Reuss, A.; Poveda, A.; Kristensen, G.; Sorio, R.; Vergote, I.; Witteveen, P.; Bamias, A.; et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014, 32, 1302–1308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kitami, K.; Yoshihara, M.; Tamauchi, S.; Sugiyama, M.; Koya, Y.; Yamakita, Y.; Fujimoto, H.; Iyoshi, S.; Uno, K.; Mogi, K.; et al. Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF-beta1/thrombospondin-1 axis. Matrix Biol. 2022, 109, 70–90. [Google Scholar] [CrossRef] [PubMed]
- Huang, H.; Wang, Z.; Zhang, Y.; Pradhan, R.N.; Ganguly, D.; Chandra, R.; Murimwa, G.; Wright, S.; Gu, X.; Maddipati, R.; et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 2022, 40, 656–673.e7. [Google Scholar] [CrossRef]
- Quijada, P.; Trembley, M.A.; Small, E.M. The Role of the Epicardium During Heart Development and Repair. Circ. Res. 2020, 126, 377–394. [Google Scholar] [CrossRef] [PubMed]
- Lie-Venema, H.; van den Akker, N.M.; Bax, N.A.; Winter, E.M.; Maas, S.; Kekarainen, T.; Hoeben, R.C.; deRuiter, M.C.; Poelmann, R.E.; Gittenberger-de Groot, A.C. Origin, fate, and function of epicardium-derived cells (EPDCs) in normal and abnormal cardiac development. Sci. World J. 2007, 7, 1777–1798. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vrancken Peeters, M.P.; Gittenberger-de Groot, A.C.; Mentink, M.M.; Poelmann, R.E. Smooth muscle cells and fibroblasts of the coronary arteries derive from epithelial-mesenchymal transformation of the epicardium. Anat. Embryol. 1999, 199, 367–378. [Google Scholar] [CrossRef]
- von Gise, A.; Zhou, B.; Honor, L.B.; Ma, Q.; Petryk, A.; Pu, W.T. WT1 regulates epicardial epithelial to mesenchymal transition through beta-catenin and retinoic acid signaling pathways. Dev. Biol. 2011, 356, 421–431. [Google Scholar] [CrossRef] [Green Version]
- Wilm, T.P.; Tanton, H.; Mutter, F.; Foisor, V.; Middlehurst, B.; Ward, K.; Benameur, T.; Hastie, N.; Wilm, B. Restricted differentiative capacity of Wt1-expressing peritoneal mesothelium in postnatal and adult mice. Sci. Rep. 2021, 11, 15940. [Google Scholar] [CrossRef]
- Sjoerd, N. Chapter 13—WT1 in cardiac development and disease. In Wilms Tumor; van den Heuvel-Eibrink, M.M., Ed.; Exon Publications: Brisbane, Australia, 2016; pp. 211–234. [Google Scholar]
- Duim, S.N.; Kurakula, K.; Goumans, M.J.; Kruithof, B.P. Cardiac endothelial cells express Wilms’ tumor-1: Wt1 expression in the developing, adult and infarcted heart. J. Mol. Cell. Cardiol. 2015, 81, 127–135. [Google Scholar] [CrossRef]
- Duim, S.N.; Smits, A.M.; Kruithof, B.P.; Goumans, M.J. The roadmap of WT1 protein expression in the human fetal heart. J. Mol. Cell. Cardiol. 2016, 90, 139–145. [Google Scholar] [CrossRef]
- Rudat, C.; Kispert, A. Wt1 and epicardial fate mapping. Circ. Res. 2012, 111, 165–169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, B.; Pu, W.T. Genetic Cre-loxP assessment of epicardial cell fate using Wt1-driven Cre alleles. Circ. Res. 2012, 111, e276–e280. [Google Scholar] [CrossRef] [Green Version]
- Tian, X.; Hu, T.; Zhang, H.; He, L.; Huang, X.; Liu, Q.; Yu, W.; He, L.; Yang, Z.; Zhang, Z.; et al. Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. Cell. Res. 2013, 23, 1075–1090. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473, 298–307. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Green Version]
- Stockmann, C.; Doedens, A.; Weidemann, A.; Zhang, N.; Takeda, N.; Greenberg, J.I.; Cheresh, D.A.; Johnson, R.S. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456, 814–818. [Google Scholar] [CrossRef] [Green Version]
- Hurwitz, H. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N. Engl. J. Med. 2004, 350, 2335–2342. [Google Scholar] [CrossRef] [Green Version]
- Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542–2550. [Google Scholar] [CrossRef] [Green Version]
- Bergers, G.; Song, S.; Meyer-Morse, N.; Bergsland, E.; Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111, 1287–1295. [Google Scholar] [CrossRef] [Green Version]
- Nisancioglu, M.H.; Betsholtz, C.; Genove, G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res. 2010, 70, 5109–5115. [Google Scholar] [CrossRef]
- Zhang, Y.; Cedervall, J.; Hamidi, A.; Herre, M.; Viitaniemi, K.; D’Amico, G.; Miao, Z.; Unnithan, R.V.M.; Vaccaro, A.; van Hooren, L.; et al. Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis. Cancer Res. 2020, 80, 3345–3358. [Google Scholar] [CrossRef] [PubMed]
- Hanson, J.; Gorman, J.; Reese, J.; Fraizer, G. Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front. Biosci. 2007, 12, 2279–2290. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McCarty, G.; Awad, O.; Loeb, D.M. WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J. Biol. Chem. 2011, 286, 43634–43643. [Google Scholar] [CrossRef] [Green Version]
- Katuri, V.; Gerber, S.; Qiu, X.; McCarty, G.; Goldstein, S.D.; Hammers, H.; Montgomery, E.; Chen, A.R.; Loeb, D.M. WT1 regulates angiogenesis in Ewing Sarcoma. Oncotarget 2014, 5, 2436–2449. [Google Scholar] [CrossRef] [Green Version]
- Timar, J.; Meszaros, L.; Orosz, Z.; Albini, A.; Raso, E. WT1 expression in angiogenic tumours of the skin. Histopathology 2005, 47, 67–73. [Google Scholar] [CrossRef]
- Wagner, N. The Wilms’ tumour suppressor WT1 is involved in endothelial cell proliferation and migration: Expression in tumour vessels in vivo. Oncogene 2008, 27, 3662–3672. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wagner, K.D.; Cherfils-Vicini, J.; Hosen, N.; Hohenstein, P.; Gilson, E.; Hastie, N.D.; Michiels, J.F.; Wagner, N. The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression. Nat. Commun. 2014, 5, 5852. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Frigolet, M.E.; Gutierrez-Aguilar, R. The colors of adipose tissue. Gac. Med. Mex. 2020, 156, 142–149. [Google Scholar] [CrossRef] [Green Version]
- Thomas, E.L. Magnetic resonance imaging of total body fat. J. Appl. Physiol. 1998, 85, 1778–1785. [Google Scholar] [CrossRef] [Green Version]
- Despres, J.P. Is visceral obesity the cause of the metabolic syndrome? Ann. Med. 2006, 38, 52–63. [Google Scholar] [CrossRef]
- Kwok, K.H.; Lam, K.S.; Xu, A. Heterogeneity of white adipose tissue: Molecular basis and clinical implications. Exp. Mol. Med. 2016, 48, e215. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cinti, S. Transdifferentiation properties of adipocytes in the adipose organ. Am. J. Physiol. Endocrinol. Metab. 2009, 297, E977–E986. [Google Scholar] [CrossRef] [PubMed]
- Chouchani, E.T.; Kazak, L.; Spiegelman, B.M. New Advances in Adaptive Thermogenesis: UCP1 and Beyond. Cell. Metab. 2019, 29, 27–37. [Google Scholar] [CrossRef] [PubMed]
- Kirschner, K.M.; Scholz, H. WT1 in Adipose Tissue: From Development to Adult Physiology. Front. Cell. Dev. Biol. 2022, 10, 854120. [Google Scholar] [CrossRef] [PubMed]
- Cohen, P.; Levy, J.D.; Zhang, Y.; Frontini, A.; Kolodin, D.P.; Svensson, K.J.; Lo, J.C.; Zeng, X.; Ye, L.; Khandekar, M.J.; et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell 2014, 156, 304–316. [Google Scholar] [CrossRef] [Green Version]
- Pischon, T.; Boeing, H.; Hoffmann, K.; Bergmann, M.; Schulze, M.B.; Overvad, K.; van der Schouw, Y.T.; Spencer, E.; Moons, K.G.; Tjonneland, A.; et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 2008, 359, 2105–2120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ohno, H.; Shinoda, K.; Spiegelman, B.M.; Kajimura, S. PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 2012, 15, 395–404. [Google Scholar] [CrossRef] [Green Version]
- Kirschner, K.M.; Foryst-Ludwig, A.; Gohlke, S.; Li, C.; Flores, R.E.; Kintscher, U.; Schupp, M.; Schulz, T.J.; Scholz, H. Wt1 haploinsufficiency induces browning of epididymal fat and alleviates metabolic dysfunction in mice on high-fat diet. Diabetologia 2022, 65, 528–540. [Google Scholar] [CrossRef]
- Chau, Y.Y.; Bandiera, R.; Serrels, A.; Martinez-Estrada, O.M.; Qing, W.; Lee, M.; Slight, J.; Thornburn, A.; Berry, R.; McHaffie, S.; et al. Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat. Cell Biol. 2014, 16, 367–375. [Google Scholar] [CrossRef] [Green Version]
- Lee, K.Y.; Luong, Q.; Sharma, R.; Dreyfuss, J.M.; Ussar, S.; Kahn, C.R. Developmental and functional heterogeneity of white adipocytes within a single fat depot. EMBO J. 2019, 38, e99291. [Google Scholar] [CrossRef]
- Westcott, G.P.; Emont, M.P.; Li, J.; Jacobs, C.; Tsai, L.; Rosen, E.D. Mesothelial cells are not a source of adipocytes in mice. Cell Rep. 2021, 36, 109388. [Google Scholar] [CrossRef] [PubMed]
- Burl, R.B.; Ramseyer, V.D.; Rondini, E.A.; Pique-Regi, R.; Lee, Y.H.; Granneman, J.G. Deconstructing Adipogenesis Induced by beta3-Adrenergic Receptor Activation with Single-Cell Expression Profiling. Cell Metab. 2018, 28, 300–309.e4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferrero, R.; Rainer, P.; Deplancke, B. Toward a Consensus View of Mammalian Adipocyte Stem and Progenitor Cell Heterogeneity. Trends Cell Biol. 2020, 30, 937–950. [Google Scholar] [CrossRef] [PubMed]
- Bochet, L.; Lehuede, C.; Dauvillier, S.; Wang, Y.Y.; Dirat, B.; Laurent, V.; Dray, C.; Guiet, R.; Maridonneau-Parini, I.; Le Gonidec, S.; et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 2013, 73, 5657–5668. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chirumbolo, S.; Bjorklund, G. Can Wnt5a and Wnt non-canonical pathways really mediate adipocyte de-differentiation in a tumour microenvironment? Eur. J. Cancer 2016, 64, 96–100. [Google Scholar] [CrossRef] [PubMed]
- Iyoshi, S.; Yoshihara, M.; Nakamura, K.; Sugiyama, M.; Koya, Y.; Kitami, K.; Uno, K.; Mogi, K.; Tano, S.; Tomita, H.; et al. Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer. Int. J. Cancer 2021, 149, 1961–1972. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Taniguchi, T.; Tomita, H.; Kanayama, T.; Mogi, K.; Koya, Y.; Yamakita, Y.; Yoshihara, M.; Kajiyama, H.; Hara, A. Regulation of Mesothelial Cell Fate during Development and Human Diseases. Int. J. Mol. Sci. 2022, 23, 11960. https://doi.org/10.3390/ijms231911960
Taniguchi T, Tomita H, Kanayama T, Mogi K, Koya Y, Yamakita Y, Yoshihara M, Kajiyama H, Hara A. Regulation of Mesothelial Cell Fate during Development and Human Diseases. International Journal of Molecular Sciences. 2022; 23(19):11960. https://doi.org/10.3390/ijms231911960
Chicago/Turabian StyleTaniguchi, Toshiaki, Hiroyuki Tomita, Tomohiro Kanayama, Kazumasa Mogi, Yoshihiro Koya, Yoshihiko Yamakita, Masato Yoshihara, Hiroaki Kajiyama, and Akira Hara. 2022. "Regulation of Mesothelial Cell Fate during Development and Human Diseases" International Journal of Molecular Sciences 23, no. 19: 11960. https://doi.org/10.3390/ijms231911960
APA StyleTaniguchi, T., Tomita, H., Kanayama, T., Mogi, K., Koya, Y., Yamakita, Y., Yoshihara, M., Kajiyama, H., & Hara, A. (2022). Regulation of Mesothelial Cell Fate during Development and Human Diseases. International Journal of Molecular Sciences, 23(19), 11960. https://doi.org/10.3390/ijms231911960